The ototoxic potentials oftwo aminoglycoside antibiotics, amikacin and gentamicin, were compared in cats, using several otoxicity assessment tecbniques. 
The ototoxic potentials oftwo aminoglycoside antibiotics, amikacin and gentamicin, were compared in cats, using Aminoglycoside antibiotics are potentially ototoxic, and this untoward effect may be manifested pmarily as cochlear or vestibular dysfinction (1) . Results of an earlier study in cats revealed amikacin, a new aminoglycosode (13) , to be toxic to the cochlear at doses not afecting vestibular fimetion (14) . In contrast, gentami- cin has been reported to cause primarily vestibular dysfunction at doses that may also be cochleotoxic (7) (8) (9) 11) . In the present study cats were treated with amikacin or gentamicin daily for extended periods of time until definitive signs of ototoxicity developed. Multiples of approximately three and six times the recommended daily human clinical doses of amikacin (15 mg/ kg per day) and gentamicin (3 mg/kg per day) (12) approximately 810, 2,500, and 6,000 Hz. The oscillator output to the speaker was monitored by a digital volt meter (Data Precision type 2440) and adjusted to produce 10-dB-step sound levels from 80 to about 120 dB. At intervals, sound intensities at the speaker face were checked by substituting a sound level meter for the animal preparation. For each sound stimulus to a control or treated cat, the observed alternating current cochlear microphonic (CM) response detected at the RW membrane was measured from the oscilloscope display in terms of microvolts from peak to peak.
In the second test mode, nerve action potentials (NAP), the negative N1 deflections, were detected at the RW after the induction by a speaker click generated from a Grass S8 stimulator. The stimulus was a 10-s train of pulses, 150 V, 0.1 ms duration, synchronized to the oscilloscope trigger sweep with a 0.1-ms delay. The superimposed responses were photographed from the oscilloscope screen for subsequent measurements in terms of microvolts of response from sweep base line to maximum deflection.
Electrophysiological assessments were not performed on ears with obvious otitis media. Past experience (14) has indicated that inflammation and associated detritus in the middle ear and on the RW will reduce the CM and NAP responses to test stimuli.
The CM data were reduced to identify the level of maximal response for each cat. Only the maximal alternating current CM amplitude measurements at 810 and 2,500 Hz were averaged for both ears. A separate average for both ears was determined for the NAP deflection response from each cat. Mean values between cats in each treatment group were used to represent results of the experiment.
Blood samples were obtained from all treated cats 2 h after the administration of the dose on the first and last treatment days and at the termination after electrophysiological deterninations 24 to 28 h after the last dose. Perilymph samples (approximately 10 IlI) were collected in a micropipette from the RW of both ears after the electrophysiological determinations were completed and were expanded with pH 6 phosphate buffer to a workable volume (0.1 ml). The serum and perilymph samples were assayed for drug concentration by the cup-plate assay method, using Bacillus subtilis ATCC 6633 as the test organism and the respective antibiotic as a standard.
Immediately after the electrophysiological assessment, the cats were sacrificed and examined for gross pathological lesions. Kidneys were submitted for histopathological assessment of renal toxicity and scored as follows: 0-none; 1-slight; 2 -moderate; 3-marked; and 4-pronounced.
RESULTS
Impaired behavioral reaction to sound was difficult to identify. The initial group of cats receiving amikacin at 90 mg/kg per day was terminated for suspected hearing impairment after 63.4 treatment days or a 5,706-mg/kg cumulative dose. However, when tested for CM and NAP reactions to sound, none ofthe ears of these cats responded. This left in question the minimum number of daily doses required to produce the end point of a perceptible but small response to sound. After this initial test with amikacin, an improved procedure for the detection of hearing deficit was employed using sounds previously recorded on a model TC-90A Sony tape cassette recorder, and treatment with amikacin was started in a second group (group 1A) of cats at 90 mg/kg per day. These VOL. 12, 1977 None of the cats treated with amikacin showed behavioral signs of vestibular dysfunction at the termination.
In contrast, cats given gentamicin were terminated for signs of vestibular dysfunction, as indicated by marked ataxia and impaired righting reflex. The high dose (18 mg/kg per day) induced these signs after an average of 41.6 treatment days, although there was a rather wide variability (29 to 60 days) in the number of doses required to produce end-point ototoxicity in all five cats. The low dose of gentamicin (9 mg/kg per day) induced similar signs in four cats after an average of 67.8 treatment days. One other animal (no. 202) receiving this aminoglycoside at 9 mg/kg per day evidenced only intermittent ataxia after 168 days when the study was arbitrarily terminated and was not included in the evaluations. Cumulative doses of gentamicin analogous to the amikacin end point or total doses were 749 mg/kg at the high dose and 610 mg/kg at the low dose. A statistical evaluation (10) revealed that these total gentamicin doses were similar.
Terminal evaluations of cochlear function are presented in Table 2 . Amikacin at both dose levels (90 and 45 mg/kg per day) produced significant and almost complete abolition of CM and NAP responses. When compared with control cats, the average CM and NAP responses for amikacin ranged from 1 to 4% and 4 to 8% at the high (group 1A) and low (group 2) doses, respectively.
Gentamicin at 18 and 9 mg/kg per day also produced significant reductions in cochlear responses although they were not detected clinically. The average level of cochlear responses after gentamicin ranged from 31 to 46% of levels determined in the control cats (Table 2 ). These observations indicate that gentamicin also has a liability to produce cochlear damage in cats, although its primary clinical ototoxic effect was on vestibular function.
During the course of the experiment, markedly reduced PRN values became evident in some gentamicin-treated cats, but this parameter did not reliably predict end-point vestibular ototoxicity when the test was performed at 7-day intervals. Repeat assessments at the termination revealed that PRN values had declined in all cats, including the controls (Table 3) . However, only the animals receiving gentamicin at 18 or 9 mg/kg per day exhibited a markedly reduced duration of nystagmus and numbers of saccades when compared with the control and amikacin groups. A borderline reduction in the number of saccades but not the duration of nystagmus was detected in the group 1 amikacin cats (90 mg/kg per day) only at a tennination after 63.4 doses, well beyond the dose time (40.7 doses, group 1A) to produce cochlear impairment, indicating a very low potential for vestibular effects with amikacin.
Appetite suppression also became evident in some cats receiving gentamicin. In contrast, the doses of amikacin were well tolerated for the duration of treatment, and no behavioral changes other than apparent hearing impairment were evident in these animals. Table 4 shows that amikacin and gentamicin produced serum levels that were dose related, and practically no accumulation was evident with either antibiotic at the dose levels em- Within limits of the numbers of animals used, a statistical evaluation (10) revealed that the dence of histological nephrotoxicity in gentamicin-treated animals was significantly greater than that in the control cats, whereas the incidence in aimal receiving amikacin was not different from controls. Since these aminoglycosides are both potentially nephrotoxic as well as ototoxic, cats with renal toxicity were not excluded frqm the evaluation.
BUN levels were monitored as indirect evidence of nephrotoxicity, but a correlation between this parameter and renal histopathology did not always exist (Table 4) . DISCUSSION It has been established that the ototoxic liability of amikacin in laboratory cats is cochlear (14) . In contrast, the clinical liability of gentamicin is considered to be primarily vestibular, although cochlear toxicity has also been observed in humans (2, 7) and in animals (6, 9) . Consequently, the end points of ototoxicity selected for this comparative study were hearing impairment for ikacin and ataxia for genta- vestibular impairment in all cats tested. Table 1 shows that similar time periods (dosThe cochleotoxic liability of amikacin was ing days) were required to produce definitive confirmed in this study, and none of the cats ototoxicity when both drugs were administered receiving this aminoglycoside exhibited behav-at a dose ratio of 5 to 1. The relationship apioral changes indicative of vestibular dysfunc-peared at both dosage levels. An examination tion. In contrast, gentamicin produced ataxia, of the total or cumulative dose also demonconfirming the vestibular liability of this anti-strated a similar ratio. The cumulative quantibiotic. However, the CM and NAP determina-ties of amikacin were 3,660 mg/kg for the 90-tions revealed that in some cats gentamicin mg/kg dose for 40.7 days or 3,525 mg/kg for the also significantly reduced the cochlear re-45-mg/kg dose for 78.3 days, respectively, as desponses. These observations with gentamicin in termined by an electrophysiological assessment cats generally agree with the clinical ototoxic of cochlear function. The analogous cumulative side effects in humans (7 
